MedTrace Logo

Intensive Monitoring Scheme of Lidocaine Cataplasms

NCT05645302 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-12-09

No results posted yet for this study

Summary

In this center, retrospective research methods are used to collect data. Patients who had used Lidocaine Cataplasms at least once were included consecutively. Taking the time when the patient first used Lidocaine Cataplasms as the starting time (the study baseline), collect the demographic characteristics of the patient, the medication scheme of Lidocaine Cataplasms and other information, as well as the medication safety and other information from the first medication to the end of medication or discharge (whichever occurs first).

Conditions

  • Adverse Reaction to Drug

Interventions

DRUG

Lidocaine Cataplasms

The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.

Sponsors & Collaborators

  • Qianfoshan Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-06
Primary Completion
2022-10-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05645302 on ClinicalTrials.gov